NCT00724841 2016-07-22
A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Terminated
Clinical Trials
7 trialsNCT00405951 2016-07-21
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)in Combination With Docetaxel for the Treatment of Non-Small Cell Lung Cancer
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Completed
NCT00407303 2016-07-21
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Completed
NCT00682981 2016-07-21
A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Completed
NCT00521144 2015-05-05
Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00719901 2015-01-12
Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT01238146 2013-06-06
Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 1/2 Withdrawn